Stockreport

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials [Yahoo! Finance]

Cassava Sciences, Inc.  (SAVA) 
Last cassava sciences, inc. earnings: 8/12 08:30 am Check Earnings Report
PDF The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Pha [Read more]